118 related articles for article (PubMed ID: 12746835)
21. Metastases of prostate cancer express estrogen receptor-beta.
Lai JS; Brown LG; True LD; Hawley SJ; Etzioni RB; Higano CS; Ho SM; Vessella RL; Corey E
Urology; 2004 Oct; 64(4):814-20. PubMed ID: 15491740
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide.
Papo N; Seger D; Makovitzki A; Kalchenko V; Eshhar Z; Degani H; Shai Y
Cancer Res; 2006 May; 66(10):5371-8. PubMed ID: 16707464
[TBL] [Abstract][Full Text] [Related]
23. Comparison of two in vivo models for prostate cancer: orthotopic and intratesticular inoculation of LNCaP or PC-3 cells.
Koshida K; Konaka H; Imao T; Egawa M; Mizokami A; Namiki M
Int J Urol; 2004 Dec; 11(12):1114-21. PubMed ID: 15663685
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
25. In vivo models of prostate cancer metastasis to bone.
Singh AS; Figg WD
J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
[TBL] [Abstract][Full Text] [Related]
26. Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein.
Yang M; Jiang P; Yamamoto N; Li L; Geller J; Moossa AR; Hoffman RM
Prostate; 2005 Mar; 62(4):374-9. PubMed ID: 15389802
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
28. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
29. Low dose, alternating electric current inhibits growth of prostate cancer.
Koreckij TD; Hill C; Azure L; Nguyen H; Kunz LL; Azure A; Corey E; Lange P; Vessella RL
Prostate; 2010 Apr; 70(5):529-39. PubMed ID: 19938042
[TBL] [Abstract][Full Text] [Related]
30. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P
Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098
[TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.
Singh LS; Berk M; Oates R; Zhao Z; Tan H; Jiang Y; Zhou A; Kirmani K; Steinmetz R; Lindner D; Xu Y
J Natl Cancer Inst; 2007 Sep; 99(17):1313-27. PubMed ID: 17728215
[TBL] [Abstract][Full Text] [Related]
32. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer and other xenografts from cells in peripheral blood of patients.
Pretlow TG; Schwartz S; Giaconia JM; Wright AL; Grimm HA; Edgehouse NL; Murphy JR; Markowitz SD; Jamison JM; Summers JL; Hamlin CR; MacLennan GT; Resnick MI; Pretlow TP; Connell CF
Cancer Res; 2000 Aug; 60(15):4033-6. PubMed ID: 10945604
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
35. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
Williams CR; Tabios R; Linehan WM; Neckers L
J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
37. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
38. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
Gabril MY; Duan W; Wu G; Moussa M; Izawa JI; Panchal CJ; Sakai H; Xuan JW
Mol Ther; 2005 Mar; 11(3):348-62. PubMed ID: 15727931
[TBL] [Abstract][Full Text] [Related]
39. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
40. Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer.
Sasaki H; Miura K; Horii A; Kaneko N; Fujibuchi W; Kiseleva L; Gu Z; Murata Y; Karasawa H; Mizoi T; Kobayashi T; Kinouchi M; Ohnuma S; Yazaki N; Unno M; Sasaki I
Cancer Sci; 2008 Apr; 99(4):711-9. PubMed ID: 18307535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
